Are you Dr. Lightfoot?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 39 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3319 Spring St
Davenport, IA 52807Phone+1 563-359-1641Fax+1 563-359-4634
Summary
- Dr. Andrew Lightfoot, MD is a general surgeon in Davenport, Iowa. He is currently licensed to practice medicine in Iowa, Illinois, and Pennsylvania. He is affiliated with Genesis Medical Center - Davenport.
Education & Training
- University of Iowa Hospitals and ClinicsResidency, Urology, 2007 - 2013
- University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 2007
Certifications & Licensure
- IA State Medical License 2007 - 2026
- IL State Medical License 2014 - 2026
- PA State Medical License 2013 - 2014
- American Board of Urology Urology
Publications & Presentations
PubMed
- 14 citationsDoes previous transurethral prostate surgery affect oncologic and continence outcomes after RARPYu-Kai Su, Benjamin F. Katz, Shailen Sehgal, Sue-Jean S. Yu, Yu-Chen Su
Journal of Robotic Surgery. 2015-08-08 - 15 citationsPositive Surgical Margin Trends In Patients With Pathologic T3 Prostate Cancer Treated With Robot Assisted Radical Prostatectomy.Andrew J. Lightfoot, Yu-Kai Su, Shailen Sehgal, Ziho Lee, Giovanni H. Greaves
Journal of Endourology. 2014-12-15 - 75 citationsMulti-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancerAndrew J. Lightfoot, Benjamin N. Breyer, Henry M. Rosevear, Bradley A. Erickson, Badrinath R. Konety
Urologic Oncology. 2014-01-01
Press Mentions
- Procarta Receives CARB-X Award of up to $9.2 MillionSeptember 17th, 2019
- Procarta Raises €1.5 Million to Develop a New Class of Antibiotics to Combat Antimicrobial ResistanceMarch 5th, 2019
- EU Referendum: Now Top Life Science Bosses Warn of Brexit Risk, Including GSK, AstraZeneca and Pfizer in Open LaterMay 8th, 2016